1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://doi.org/10.1080/14737167.2024.2319607
DC FieldValue
dc.titleCost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
dc.contributor.authorCheng Ean Chee
dc.contributor.authorJasmeet Singh Khara
dc.contributor.authorJohn Cheong
dc.contributor.authorJek Fong
dc.contributor.authorSivabalan Sivanesan
dc.contributor.authorJian Yi Choy
dc.contributor.authorMeibo Hu
dc.contributor.authorAmrita Viswambaram
dc.contributor.authorHan Chong Toh
dc.date.accessioned2024-06-24T06:22:45Z
dc.date.available2024-06-24T06:22:45Z
dc.date.issued2024-05-22
dc.identifier.citationCheng Ean Chee, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Jian Yi Choy, Meibo Hu, Amrita Viswambaram, Han Chong Toh (2024-05-22). Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research 24 (5) : 631-641. ScholarBank@NUS Repository. https://doi.org/10.1080/14737167.2024.2319607
dc.identifier.issn1473-7167
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/249007
dc.publisherTaylor & Francis
dc.sourceTaylor & Francis
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1080/14737167.2024.2319607
dc.description.sourcetitleExpert Review of Pharmacoeconomics & Outcomes Research
dc.description.volume24
dc.description.issue5
dc.description.page631-641
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10.108014737167.2024.2319607.zip1.66 MBZIP

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.